# WIA-GENOME_EDITING Standard

[![Version](https://img.shields.io/badge/version-1.0.0-blue.svg)]()
[![License](https://img.shields.io/badge/license-MIT-green.svg)]()
[![Standard](https://img.shields.io/badge/WIA-Standard-purple.svg)]()


**Version:** 1.0
**Status:** FULL Implementation
**Created:** 2026-01-12
**Philosophy:** 홍익인간 (弘益人間) - Benefit All Humanity

---

## Overview

The WIA-GENOME_EDITING standard provides comprehensive specifications, tools, and educational materials for genome editing technologies including CRISPR-Cas9, base editing, prime editing, and FDA-approved gene therapies.

This standard covers the complete genome editing ecosystem from molecular mechanisms to clinical applications, with particular focus on:

- **CRISPR-Cas9**: Guide RNA design, off-target prediction, delivery methods
- **Base Editing**: Adenine (ABE) and cytosine (CBE) base editors for precise A→G and C→T conversions
- **Prime Editing**: PE5 system for all 12 base conversions, insertions, and deletions
- **Gene Therapy**: FDA-approved Casgevy for sickle cell disease and β-thalassemia
- **Safety**: Off-target detection, validation protocols, regulatory compliance
- **Ethics**: Responsible use guidelines and ethical frameworks

---

## Directory Structure

```
WIA-GENOME_EDITING/
├── spec/
│   ├── PHASE-1-DATA-FORMAT.md      (16 KB) - Data structures and formats
│   ├── PHASE-2-API-INTERFACE.md    (21 KB) - RESTful API specifications
│   ├── PHASE-3-PROTOCOL.md         (26 KB) - Experimental and clinical protocols
│   └── PHASE-4-INTEGRATION.md      (34 KB) - System integration patterns
├── cli/
│   └── wia-genome-editing.sh       (24 KB) - Command-line interface tool
├── ebook/
│   ├── en/                         (9 files, 169 KB total)
│   │   ├── index.html              (23 KB)
│   │   ├── chapter-01.html         (32 KB) - Introduction to Genome Editing
│   │   ├── chapter-02.html         (19 KB) - Data Structures
│   │   ├── chapter-03.html         (16 KB) - CRISPR-Cas9: The Foundation
│   │   ├── chapter-04.html         (16 KB) - Base Editing: Precision Medicine
│   │   ├── chapter-05.html         (16 KB) - Prime Editing: Search-and-Replace
│   │   ├── chapter-06.html         (16 KB) - Gene Therapy Applications
│   │   ├── chapter-07.html         (16 KB) - Safety and Ethical Considerations
│   │   └── chapter-08.html         (16 KB) - Future Directions
│   └── ko/                         (9 files, 120 KB total)
│       ├── index.html              (11 KB)
│       └── chapter-01.html to chapter-08.html (15 KB each)
└── README.md                       (this file)
```

**Total Files:** 23
**Total Size:** ~310 KB

---

## Specification Files (Phase 1-4)

### Phase 1: Data Format Specification (16 KB)

Defines standardized data structures for:
- **Genomic Sequences**: FASTA, FASTQ, BAM/SAM, VCF formats
- **Guide RNAs**: Design parameters, scoring metrics, off-target predictions
- **Base Editing**: ABE and CBE outcome data structures
- **Prime Editing**: pegRNA design and editing outcome formats
- **Gene Therapy**: Casgevy manufacturing and clinical data (BCL11A enhancer editing)
- **Off-Target Analysis**: GUIDE-seq and CIRCLE-seq result formats
- **Validation Metrics**: NGS quality control and safety assessments

### Phase 2: API Interface Specification (21 KB)

RESTful API specifications including:
- **Sequence Management**: Upload, retrieve, and analyze genomic sequences
- **CRISPR Design**: Guide RNA design and off-target prediction endpoints
- **Base Editing**: ABE/CBE design, simulation, and optimization APIs
- **Prime Editing**: PE5 design and efficiency optimization
- **Validation**: NGS-based editing outcome validation
- **Clinical Data**: Patient registration, treatment tracking, outcomes
- **Safety Reporting**: Adverse event reporting and safety analysis

Base URL: `https://api.wia-genome-editing.org/v1`

### Phase 3: Protocol Specification (26 KB)

Comprehensive protocols for:
- **CRISPR-Cas9**: Guide RNA design workflow, in vitro editing, validation
- **Base Editing**: ABE8.20-m and BE4max protocols for therapeutic applications
- **Prime Editing**: PE5 system with pegRNA and ngRNA design
- **Gene Therapy**: Casgevy manufacturing protocol (CD34+ cell editing)
  - Mobilization and apheresis
  - Cell processing and CRISPR editing
  - Quality control testing (≥60% editing efficiency)
  - Conditioning and infusion
  - Clinical outcomes (91-97% transfusion independence)
- **Safety Validation**: Off-target detection (GUIDE-seq, CIRCLE-seq, targeted NGS)
- **Clinical Trials**: Phase I/II protocol design and regulatory compliance

### Phase 4: Integration Specification (34 KB)

Integration with existing systems:
- **EHR Integration**: HL7 FHIR resources for genome editing data
- **LIMS Integration**: Sample tracking and chain of custody
- **Bioinformatics Pipelines**: Nextflow and Snakemake workflows
- **Cloud Platforms**: AWS, GCP, Azure deployment architectures
- **Research Platforms**: Benchling and SnapGene integration
- **Regulatory Systems**: FDA CBER, ClinicalTrials.gov submissions
- **Data Repositories**: ClinVar, gnomAD, COSMIC integration
- **AI/ML Platforms**: TensorFlow and scikit-learn model integration

---

## CLI Tool

### Installation

```bash
# Clone repository
git clone https://github.com/WIA-Official/wia-standards.git
cd wia-standards/standards/WIA-GENOME_EDITING/cli

# Make executable
chmod +x wia-genome-editing.sh

# Set API key
export WIA_API_KEY="your-api-key-here"

# Test installation
./wia-genome-editing.sh --version
```

### Available Commands

```bash
# Analyze genomic sequence
./wia-genome-editing.sh sequence-analyze hbb_sequence.fasta

# Design genome edit
./wia-genome-editing.sh edit-design SEQ-001 5227021 base_editor

# Plan CRISPR editing
./wia-genome-editing.sh crispr-plan HBB E6V

# Simulate base editing
./wia-genome-editing.sh simulate base_edit

# Validate editing outcomes
./wia-genome-editing.sh validate BE-001 sequencing_data.fastq.gz

# Generate report
./wia-genome-editing.sh report BE-001 html

# Manage configuration
./wia-genome-editing.sh config set api_url https://api.example.com
```

### Features

- ✅ Sequence analysis and variant detection
- ✅ Guide RNA design (CRISPR, base editor, prime editor)
- ✅ Off-target prediction and safety assessment
- ✅ Editing outcome simulation
- ✅ Validation with NGS data
- ✅ Comprehensive reporting (text, JSON, HTML)
- ✅ Configuration management
- ✅ API integration with WIA-GENOME_EDITING platform

---

## Ebooks

### English Ebook (169 KB, 9 files)

Comprehensive guide covering:

**Chapter 1: Introduction to Genome Editing** (32 KB)
- History: ZFNs → TALENs → CRISPR → Base Editors → Prime Editors
- 2020 Nobel Prize (Doudna & Charpentier)
- Types of edits: knockout, correction, insertion, regulation
- FDA approval of Casgevy (2024)
- 8 review questions, 7 key takeaways, 2 tables

**Chapter 2: Data Structures** (19 KB)
- Genomic formats: FASTA, FASTQ, BAM, VCF
- Guide RNA specifications
- Editing outcome data structures
- Clinical-grade validation (Q30, 50,000x depth)
- HL7 FHIR integration
- 7 review questions, 7 key takeaways, 2 tables

**Chapters 3-8** (16 KB each)
- CRISPR-Cas9 mechanisms and optimization
- Base editing (ABE & CBE) for precision medicine
- Prime editing (PE5) for all edit types
- Gene therapy (Casgevy clinical data)
- Safety and ethics (off-targets, regulations)
- Future directions (AI, in vivo editing)
- Each chapter: 5+ review questions, 5+ key takeaways, 2+ tables

### Korean Ebook (120 KB, 9 files)

Complete Korean translation with:
- Professional Korean terminology
- Cultural context and local examples
- Same comprehensive coverage as English version
- Index (11 KB) + 8 chapters (15 KB each)
- All chapters include review questions, key takeaways, tables

---

## Key Concepts Covered

### CRISPR-Cas9
- **Mechanism**: Cas9 nuclease + guide RNA → double-strand break → NHEJ or HDR
- **PAM Sequence**: NGG for SpCas9 (target recognition requirement)
- **Applications**: Gene knockout, correction, insertion
- **Efficiency**: 50-90% on-target editing
- **Limitation**: Off-target effects, indels

### Base Editing
- **ABE (Adenine Base Editor)**: A→G conversion without DSB
- **CBE (Cytosine Base Editor)**: C→T conversion without DSB
- **Editing Window**: Positions 4-8 from PAM
- **Efficiency**: 50-80% precise editing
- **Product Purity**: 85-95%
- **Application**: HbS E6V correction for sickle cell disease

### Prime Editing
- **Mechanism**: Cas9 nickase + reverse transcriptase + pegRNA
- **Capability**: All 12 base conversions, insertions, deletions
- **Efficiency**: 30-60% precise editing
- **Precision**: 90-98% (desired edit / total edits)
- **Advantage**: No DSB, no donor template required

### Casgevy (FDA-Approved 2024)
- **Indication**: Sickle cell disease and transfusion-dependent β-thalassemia
- **Target**: BCL11A erythroid-specific enhancer
- **Mechanism**: CRISPR-Cas9 disruption → fetal hemoglobin reactivation
- **Efficacy**: 97% (SCD), 91% (TDT) transfusion independence
- **Manufacturing**: Ex vivo editing of autologous CD34+ cells
- **Editing Efficiency**: ≥60% required for release

---

## Quality Requirements

### Clinical-Grade Standards

| Parameter | Threshold | Purpose |
|-----------|-----------|---------|
| Base Quality | Q30 (99.9%) | Accurate variant calling |
| Coverage Depth | 50,000x | Detect rare editing events |
| Mapping Quality | ≥60 | Confident alignment |
| On-Target Efficiency | ≥50% | Therapeutic efficacy |
| Off-Target Rate | ≤1% of on-target | Patient safety |
| Product Purity | ≥85% | Minimize unwanted products |
| Cell Viability | ≥70% | Manufacturing yield |

### Manufacturing QC (Casgevy)
- CD34+ purity: ≥80%
- Editing efficiency: ≥60%
- Sterility: Pass (14-day culture)
- Mycoplasma: Negative (PCR)
- Endotoxin: <5 EU/kg

---

## Safety and Ethics

### Off-Target Detection Methods
- **Computational**: Cas-OFFinder, CRISPOR predictions
- **GUIDE-seq**: Genome-wide DSB detection in cells
- **CIRCLE-seq**: In vitro cleavage site mapping
- **Targeted NGS**: Deep sequencing of predicted sites (10,000-50,000x)

### Regulatory Frameworks
- **FDA**: IND application, BLA for approval (21 CFR Part 11)
- **EMA**: ATMP regulation, CAT evaluation
- **ICH**: Good Clinical Practice (GCP)
- **CLIA**: Clinical laboratory standards

### Ethical Guidelines
- ❌ Germline editing (international moratorium)
- ✅ Somatic cell editing for disease treatment
- ✅ Informed consent and patient autonomy
- ✅ Equitable access to therapies
- ✅ Long-term safety monitoring (15 years)

---

## Real-World Clinical Data

### Casgevy Clinical Trials

**Sickle Cell Disease (n=30)**
- Transfusion independence: 97% (29/30)
- Vaso-occlusive crisis resolution: 95%
- Median HbF at 12 months: 42.5%
- Median total Hb: 12.3 g/dL

**β-Thalassemia (n=34)**
- Transfusion independence: 91% (31/34)
- Median HbF at 12 months: 40.8%
- Median total Hb: 11.9 g/dL

**Safety Profile**
- No graft failure
- No treatment-related deaths
- Common AEs: febrile neutropenia, mucositis (conditioning-related)
- Engraftment: Day 23 median

---

## Use Cases

### Research Applications
- Systematic gene knockout screens
- Disease modeling (patient iPSCs)
- Drug target validation
- Genetic interaction studies
- CRISPR libraries (genome-wide)

### Therapeutic Applications
- Sickle cell disease (Casgevy - approved)
- β-Thalassemia (Casgevy - approved)
- CAR-T cancer therapy (approved)
- HIV resistance (CCR5 knockout - Phase II)
- Leber congenital amaurosis (CEP290 - Phase III)
- Duchenne muscular dystrophy (DMD - Phase I/II)

### Agricultural Applications
- Disease-resistant crops
- Drought tolerance
- Nutritional enhancement
- Allergen reduction
- Hornless cattle (animal welfare)

---

## Future Directions

### Emerging Technologies
- **Next-Gen Editors**: Cas12, Cas13, enhanced specificity variants
- **Epigenome Editing**: CRISPRa/i for gene regulation without DNA changes
- **In Vivo Delivery**: AAV, LNP for direct tissue editing
- **Multi-Edit Systems**: Simultaneous editing of multiple targets

### AI Integration
- Guide RNA design optimization
- Off-target prediction (deep learning)
- Editing outcome prediction
- Patient stratification
- Personalized therapy design

### Regulatory Evolution
- Streamlined approval pathways
- Real-world evidence acceptance
- International harmonization
- Adaptive trial designs

---

## References

1. **FDA Approval**: Casgevy (exagamglogene autotemcel) BLA 125755, January 16, 2024
2. **Clinical Efficacy**: Frangoul et al., "Exagamglogene Autotemcel for Sickle Cell Disease and β-Thalassemia," NEJM, 2021
3. **CRISPR Discovery**: Jinek et al., "A Programmable Dual-RNA-Guided DNA Endonuclease," Science, 2012
4. **Base Editing**: Gaudelli et al., "Programmable base editing of A•T to G•C," Nature, 2017
5. **Prime Editing**: Anzalone et al., "Search-and-replace genome editing without double-strand breaks," Nature, 2019
6. **Off-Target Detection**: Tsai et al., "GUIDE-seq enables genome-wide profiling of off-target cleavage," Nat Biotechnol, 2015

---

## Contributing

This standard is maintained by the WIA Technical Committee. For contributions or feedback:

- **GitHub**: https://github.com/WIA-Official/wia-standards
- **Email**: technical-committee@wia.org
- **Issues**: https://github.com/WIA-Official/wia-standards/issues

---

## License

© 2026 World Certification Industry Association (WIA)

This standard is published under the WIA Open Standard License, permitting implementation and use with attribution.

---

## Version History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2026-01-12 | Initial FULL specification release |

---

**홍익인간 (弘益人間) · Benefit All Humanity**

*WIA-GENOME_EDITING Standard - Advancing precision medicine through standardized genome editing protocols*

---

**홍익인간 (弘益人間) - Benefit All Humanity** 🌍
